Pleomorphic xanthoastrocytoma (PXA) is a rare tumor with good prognosis after surgery. Few cases of anaplastic PXA (either de novo or secondary to transformation of a recurrent low grade PXA) have been reported. Moreover, primary anaplastic PXA with dissemination at diagnosis has been described only in two patients, to our knowledge. We report the first case of primary multicentric anaplastic PXA and discuss its atypical features and the pertinent literature.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2012.09.046DOI Listing

Publication Analysis

Top Keywords

anaplastic pxa
12
primary multicentric
8
multicentric anaplastic
8
pleomorphic xanthoastrocytoma
8
atypical features
8
pxa
5
anaplastic
4
anaplastic pleomorphic
4
xanthoastrocytoma atypical
4
features pleomorphic
4

Similar Publications

Article Synopsis
  • Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor first reported in 1979, mostly found in the temporoparietal lobe, and it usually has a good outcome.
  • The most common symptoms are seizures, but about 50-78% of patients may also have psychiatric issues like anxiety, depression, or even schizophrenia-like symptoms.
  • A recent case involved a 26-year-old man who had seizures and schizophrenia-like psychosis for 5 years; after surgery, his condition improved, showing how important surgery can be for this type of tumor.
View Article and Find Full Text PDF
Article Synopsis
  • - The paper discusses recurrent pleomorphic xanthoastrocytoma (PXA) with leptomeningeal dissemination, emphasizing the difficult management of such cases and the potential benefits of radiotherapy for symptom relief and extending life.
  • - A specific case is described of a 27-year-old woman with recurrent anaplastic PXA who, after multiple treatments and disease progressions, benefited from radiotherapy to the spinal axis, achieving clinical stability.
  • - This case highlights the significance of considering palliative radiotherapy as a strategy to enhance quality of life and possibly prolong survival for patients with challenging PXA conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Anaplastic ganglioglioma (GG) is a rare tumor with glial components that can become more aggressive over time, particularly in pediatric patients aged 9-16.
  • In a study of three patients with BRAF p.V600E mutations, initial low-grade tumors transformed into higher-grade tumors at recurrence after a period ranging from 20 months to 7 years.
  • The research suggests that the progression to a more malignant state in gangliogliomas may involve the inactivation of the CDKN2A/B genes, even though these deletions were not found in all initial tumors.
View Article and Find Full Text PDF

Purpose: Although fewer than 5% of high-grade gliomas (HGG) are BRAF-V600E mutated, these tumors are notable as BRAF-targeted therapy shows efficacy for some populations. The purpose of this study was to evaluate response to the combination of encorafenib with binimetinib in adults with recurrent BRAF-V600-mutated HGG.

Patients And Methods: In this phase 2, open-label, Adult Brain Tumor Consortium (ABTC) trial (NCT03973918), encorafenib and binimetinib were administered at their FDA-approved doses continuously in 28-day cycles.

View Article and Find Full Text PDF

We present a unique case of a 45-year-old male with cerebral palsy, who experienced walking difficulties and altered consciousness. The initial MRI revealed an intraventricular mass that rapidly enlarged over a month, consisting of two distinct components with different characteristics on CT and MRI, and was associated with agenesis of the corpus callosum. Despite initial treatment, surgical intervention was necessary, where preoperative imaging suggested an exophytically growing glioblastoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!